NRX Pharmaceuticals (NRXP) Liabilities and Shareholders Equity (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $11.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 56.82% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $44.7 million, a 113.16% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 254.86% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $11.9 million, down from $13.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NRXP reached as high as $43.6 million in Q1 2022 and fell as low as $3.7 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $15.2 million across 5 years, with a median of $13.0 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity soared 623.34% in 2022 and slumped 82.61% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $25.8 million in 2022, then tumbled by 71.66% to $7.3 million in 2023, then sank by 50.09% to $3.7 million in 2024, then soared by 254.86% to $13.0 million in 2025, then slipped by 8.13% to $11.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $11.9 million in Q1 2026, $13.0 million in Q4 2025, and $15.0 million in Q3 2025.